ClinicalTrials.govpublic full text
AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients
leukemia, nonlymphoblastic, acute, acute myeloid leukemia, cytarabine postremission dosage, risk adapted treatment strategy, allogeneic stem cell transplantation, autologous stem cell transplantation, interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 826959
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.